These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 11078979)

  • 1. Somatostatin analogs in the treatment of acromegaly: the choice is now possible.
    Chanson P
    Eur J Endocrinol; 2000 Nov; 143(5):573-5. PubMed ID: 11078979
    [No Abstract]   [Full Text] [Related]  

  • 2. Somatostatin analogs as primary medical therapy for acromegaly.
    Danoff A; Kleinberg D
    Endocrine; 2003 Apr; 20(3):291-7. PubMed ID: 12721510
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medical therapy with somatostatin analogues for acromegaly.
    Sassolas G
    Eur J Endocrinol; 1995 Dec; 133(6):675-7. PubMed ID: 8548050
    [No Abstract]   [Full Text] [Related]  

  • 4. The therapeutic value of somatostatin and its analogues.
    Farooqi S; Bevan JS; Sheppard MC; Wass JA
    Pituitary; 1999 Jun; 2(1):79-88. PubMed ID: 11081176
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Somatostatin analogs in medical treatment of acromegaly.
    Racine MS; Barkan AL
    Endocrine; 2003 Apr; 20(3):271-8. PubMed ID: 12721507
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of efficacy and tolerability of somatostatin analogs and other therapies for acromegaly.
    Burt MG; Ho KK
    Endocrine; 2003 Apr; 20(3):299-305. PubMed ID: 12721511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New medical treatment for acromegaly.
    van der Lely AJ; de Herder WW; Lamberts SW
    Pituitary; 1999 Jun; 2(1):89-92. PubMed ID: 11081177
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pasireotide as a new second-line treatment option].
    Strathaus RS
    Med Monatsschr Pharm; 2015 May; 38(5):194-5. PubMed ID: 26364410
    [No Abstract]   [Full Text] [Related]  

  • 9. Impact of somatostatin analogs on the heart in acromegaly: a metaanalysis.
    Maison P; Tropeano AI; Macquin-Mavier I; Giustina A; Chanson P
    J Clin Endocrinol Metab; 2007 May; 92(5):1743-7. PubMed ID: 17311857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination treatment with somatostatin analogues and pegvisomant in acromegaly.
    Neggers SJ; van der Lely AJ
    Growth Horm IGF Res; 2011 Jun; 21(3):129-33. PubMed ID: 21498099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of a GH receptor antagonist in patients with acromegaly resistant to somatostatin analogs.
    Colao A; Pivonello R; Cappabianca P; Auriemma RS; De Martino MC; Ciccarelli A; de Divitiis E; Lombardi G
    J Endocrinol Invest; 2003; 26(10 Suppl):53-6. PubMed ID: 15497660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Growth-hormone and prolactin excess.
    Colao A; Lombardi G
    Lancet; 1998 Oct; 352(9138):1455-61. PubMed ID: 9808008
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term efficacy and safety of combined treatment of somatostatin analogs and pegvisomant in acromegaly.
    Neggers SJ; van Aken MO; Janssen JA; Feelders RA; de Herder WW; van der Lely AJ
    J Clin Endocrinol Metab; 2007 Dec; 92(12):4598-601. PubMed ID: 17895318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of pre-treatment with somatostatin analogs on surgical management of acromegalic patients referred to a single center.
    Bacigaluppi S; Gatto F; Anania P; Bragazzi NL; Rossi DC; Benvegnu G; Nazzari E; Spaziante R; Giusti M; Ferone D; Zona G
    Endocrine; 2016 Mar; 51(3):524-33. PubMed ID: 25982150
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist.
    Jørgensen JO; Feldt-Rasmussen U; Frystyk J; Chen JW; Kristensen LØ; Hagen C; Ørskov H
    J Clin Endocrinol Metab; 2005 Oct; 90(10):5627-31. PubMed ID: 16046586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evolution of (18)FDG pituitary uptake after medical control of acromegaly.
    Maiza JC; Revel C
    Pituitary; 2014 Jun; 17(3):296-7. PubMed ID: 23982451
    [No Abstract]   [Full Text] [Related]  

  • 17. Regression of acromegalic left ventricular hypertrophy after lanreotide (a slow-release somatostatin analog).
    Hradec J; Kral J; Janota T; Krsek M; Hana V; Marek J; Malik M
    Am J Cardiol; 1999 May; 83(10):1506-9, A8. PubMed ID: 10335774
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of somatostatin analogs on glucose homeostasis: a metaanalysis of acromegaly studies.
    Mazziotti G; Floriani I; Bonadonna S; Torri V; Chanson P; Giustina A
    J Clin Endocrinol Metab; 2009 May; 94(5):1500-8. PubMed ID: 19208728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Perspectives of new potential therapeutic applications of somatostatin analogs.
    Pawlikowski M; Melen-Mucha G
    Neuro Endocrinol Lett; 2003; 24(1-2):21-7. PubMed ID: 12743527
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term effects of the combination of pegvisomant with somatostatin analogs (SSA) on glucose homeostasis in non-diabetic patients with active acromegaly partially resistant to SSA.
    De Marinis L; Bianchi A; Fusco A; Cimino V; Mormando M; Tilaro L; Mazziotti G; Pontecorvi A; Giustina A
    Pituitary; 2007; 10(3):227-32. PubMed ID: 17484056
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.